MTOR as a multifunctional therapeutic target in HIV infection

Ferdinando Nicoletti, Paolo Fagone, Pierluigi Meroni, James McCubrey, Klaus Bendtzen

Research output: Contribution to journalArticle

54 Citations (Scopus)

Abstract

Patients undergoing long-term highly active antiretroviral therapy treatment are probably at a higher risk of various HIV-related complications. Hyperactivation of The mammalian target of rapamycin (mTOR) has been found to contribute to dysregulated apoptosis and autophagy which determine CD4 +-T-cell loss, impaired function of innate immunity and development of neurocognitive disorders. Dysregulated mTOR activation has also been shown to play a key part in the development of nephropathy and in the pathogenesis of HIV-associated malignancies. These studies strongly support a multifunctional key role for mTOR in the pathogenesis of HIV-related disorders and suggest that specific mTOR inhibitors could represent a novel approach for the prevention and treatment of these pathologies.

Original languageEnglish
Pages (from-to)715-721
Number of pages7
JournalDrug Discovery Today
Volume16
Issue number15-16
DOIs
Publication statusPublished - Aug 2011

Fingerprint

Sirolimus
HIV Infections
HIV
Highly Active Antiretroviral Therapy
Autophagy
Therapeutics
Innate Immunity
Apoptosis
Pathology
T-Lymphocytes
Neoplasms

ASJC Scopus subject areas

  • Drug Discovery
  • Pharmacology

Cite this

MTOR as a multifunctional therapeutic target in HIV infection. / Nicoletti, Ferdinando; Fagone, Paolo; Meroni, Pierluigi; McCubrey, James; Bendtzen, Klaus.

In: Drug Discovery Today, Vol. 16, No. 15-16, 08.2011, p. 715-721.

Research output: Contribution to journalArticle

Nicoletti, F, Fagone, P, Meroni, P, McCubrey, J & Bendtzen, K 2011, 'MTOR as a multifunctional therapeutic target in HIV infection', Drug Discovery Today, vol. 16, no. 15-16, pp. 715-721. https://doi.org/10.1016/j.drudis.2011.05.008
Nicoletti, Ferdinando ; Fagone, Paolo ; Meroni, Pierluigi ; McCubrey, James ; Bendtzen, Klaus. / MTOR as a multifunctional therapeutic target in HIV infection. In: Drug Discovery Today. 2011 ; Vol. 16, No. 15-16. pp. 715-721.
@article{c0abc23edfc847b8b05b77a3a95b2d73,
title = "MTOR as a multifunctional therapeutic target in HIV infection",
abstract = "Patients undergoing long-term highly active antiretroviral therapy treatment are probably at a higher risk of various HIV-related complications. Hyperactivation of The mammalian target of rapamycin (mTOR) has been found to contribute to dysregulated apoptosis and autophagy which determine CD4 +-T-cell loss, impaired function of innate immunity and development of neurocognitive disorders. Dysregulated mTOR activation has also been shown to play a key part in the development of nephropathy and in the pathogenesis of HIV-associated malignancies. These studies strongly support a multifunctional key role for mTOR in the pathogenesis of HIV-related disorders and suggest that specific mTOR inhibitors could represent a novel approach for the prevention and treatment of these pathologies.",
author = "Ferdinando Nicoletti and Paolo Fagone and Pierluigi Meroni and James McCubrey and Klaus Bendtzen",
year = "2011",
month = "8",
doi = "10.1016/j.drudis.2011.05.008",
language = "English",
volume = "16",
pages = "715--721",
journal = "Drug Discovery Today",
issn = "1359-6446",
publisher = "Elsevier Limited",
number = "15-16",

}

TY - JOUR

T1 - MTOR as a multifunctional therapeutic target in HIV infection

AU - Nicoletti, Ferdinando

AU - Fagone, Paolo

AU - Meroni, Pierluigi

AU - McCubrey, James

AU - Bendtzen, Klaus

PY - 2011/8

Y1 - 2011/8

N2 - Patients undergoing long-term highly active antiretroviral therapy treatment are probably at a higher risk of various HIV-related complications. Hyperactivation of The mammalian target of rapamycin (mTOR) has been found to contribute to dysregulated apoptosis and autophagy which determine CD4 +-T-cell loss, impaired function of innate immunity and development of neurocognitive disorders. Dysregulated mTOR activation has also been shown to play a key part in the development of nephropathy and in the pathogenesis of HIV-associated malignancies. These studies strongly support a multifunctional key role for mTOR in the pathogenesis of HIV-related disorders and suggest that specific mTOR inhibitors could represent a novel approach for the prevention and treatment of these pathologies.

AB - Patients undergoing long-term highly active antiretroviral therapy treatment are probably at a higher risk of various HIV-related complications. Hyperactivation of The mammalian target of rapamycin (mTOR) has been found to contribute to dysregulated apoptosis and autophagy which determine CD4 +-T-cell loss, impaired function of innate immunity and development of neurocognitive disorders. Dysregulated mTOR activation has also been shown to play a key part in the development of nephropathy and in the pathogenesis of HIV-associated malignancies. These studies strongly support a multifunctional key role for mTOR in the pathogenesis of HIV-related disorders and suggest that specific mTOR inhibitors could represent a novel approach for the prevention and treatment of these pathologies.

UR - http://www.scopus.com/inward/record.url?scp=80051665056&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=80051665056&partnerID=8YFLogxK

U2 - 10.1016/j.drudis.2011.05.008

DO - 10.1016/j.drudis.2011.05.008

M3 - Article

C2 - 21624501

AN - SCOPUS:80051665056

VL - 16

SP - 715

EP - 721

JO - Drug Discovery Today

JF - Drug Discovery Today

SN - 1359-6446

IS - 15-16

ER -